SG11201407162SA - Methods for the treatment of diabetic retinopathy and other ophthalmic diseases - Google Patents

Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Info

Publication number
SG11201407162SA
SG11201407162SA SG11201407162SA SG11201407162SA SG11201407162SA SG 11201407162S A SG11201407162S A SG 11201407162SA SG 11201407162S A SG11201407162S A SG 11201407162SA SG 11201407162S A SG11201407162S A SG 11201407162SA SG 11201407162S A SG11201407162S A SG 11201407162SA
Authority
SG
Singapore
Prior art keywords
treatment
methods
diabetic retinopathy
ophthalmic diseases
ophthalmic
Prior art date
Application number
SG11201407162SA
Other languages
English (en)
Inventor
Claes Olof Bavik
Susan Hayes Henry
Ryo Kubota
Vladimir A Kuksa
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of SG11201407162SA publication Critical patent/SG11201407162SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11201407162SA 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases SG11201407162SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643058P 2012-05-04 2012-05-04
US201261643178P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201361781907P 2013-03-14 2013-03-14
PCT/US2013/039562 WO2013166449A2 (fr) 2012-05-04 2013-05-03 Procédés pour le traitement de la rétinopathie diabétique et d'autres maladies ophtalmiques

Publications (1)

Publication Number Publication Date
SG11201407162SA true SG11201407162SA (en) 2014-11-27

Family

ID=49515046

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407162SA SG11201407162SA (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Country Status (18)

Country Link
US (3) US9957224B2 (fr)
EP (2) EP3741742A1 (fr)
JP (5) JP2015518491A (fr)
KR (1) KR20150013240A (fr)
CN (3) CN107865830A (fr)
AU (1) AU2013256029A1 (fr)
BR (1) BR112014027571B1 (fr)
CA (1) CA2872433C (fr)
EA (1) EA201492031A1 (fr)
ES (1) ES2792923T3 (fr)
HK (2) HK1246646A1 (fr)
IL (1) IL235446A0 (fr)
MX (2) MX2014013341A (fr)
PH (1) PH12014502449A1 (fr)
SG (1) SG11201407162SA (fr)
TW (1) TW201406707A (fr)
WO (1) WO2013166449A2 (fr)
ZA (1) ZA201408592B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014151622A (ru) 2007-10-05 2015-08-20 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
CN104703598A (zh) 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
EP2970099A4 (fr) * 2013-03-12 2016-12-21 Acucela Inc Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques
EP2967999B1 (fr) 2013-03-14 2017-04-19 Optimedica Corporation Capsulo-vitrectomie au laser
AU2015243261B2 (en) 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2018223810B2 (en) * 2017-02-27 2022-04-21 Case Western Reserve University Visual cycle modulators
CN111526779B (zh) * 2017-12-28 2023-07-11 株式会社尼康 图像处理方法、图像处理程序、图像处理装置、图像显示装置、以及图像显示方法
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
EP3817808A4 (fr) 2018-07-07 2022-04-06 Acucela Inc. Dispositif de prévention de l'hypoxie rétinienne
CA3107824A1 (fr) 2018-07-30 2020-02-06 Acucela Inc. Conceptions optiques de lentille de contact electronique destinees a ralentir la progression de la myopie
JP2022512706A (ja) * 2018-10-16 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 眼科におけるＡｋｔ阻害剤の使用
CN112804999B (zh) * 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
US20220230307A1 (en) * 2019-05-31 2022-07-21 Nikon Corporation Image processing method, image processing device, image processing program
WO2021022193A1 (fr) 2019-07-31 2021-02-04 Acucela Inc. Dispositif de projection d'images sur la rétine
US11733545B2 (en) 2019-09-16 2023-08-22 Acucela Inc. Assembly process for an electronic soft contact lens designed to inhibit progression of myopia
TW202203521A (zh) 2020-02-21 2022-01-16 美商艾尤席拉有限公司 電子隱形眼鏡之充電盒
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
CN115668038A (zh) 2020-05-13 2023-01-31 奥克塞拉有限公司 用于近视治疗的电可切换眼镜
AU2021287803A1 (en) 2020-06-08 2022-10-27 Acucela Inc. Stick on devices using peripheral defocus to treat progressive refractive error
CN115698832A (zh) 2020-06-08 2023-02-03 奥克塞拉有限公司 用于治疗散光的非对称投影透镜
KR20230020951A (ko) 2020-06-08 2023-02-13 어큐셀라 인코포레이티드 굴절 이상을 치료하기 위한 주변 망막에 대한 디포커스된 이미지의 투영
US11281022B2 (en) * 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
CA3218950A1 (fr) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methodes et compositions pour le traitement d'une maladie neovasculaire oculaire
WO2022255332A1 (fr) * 2021-06-03 2022-12-08 国立大学法人大阪大学 Procédé de dépistage de la rétinopathie du prématuré, appareil de dépistage de la rétinopathie du prématuré, et modèle appris

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
TWI260327B (en) * 2001-11-09 2006-08-21 Osi Eyetech Inc Pharmaceutical compositions for treating ocular neovascular diseases
WO2005087210A2 (fr) * 2004-03-17 2005-09-22 Lars Michael Larsen Prevention de la retinopathie par inhibition du cycle visuel
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
JP5371953B2 (ja) * 2007-04-20 2013-12-18 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療するスチレニル誘導体化合物
WO2009005794A2 (fr) * 2007-06-29 2009-01-08 Acucela, Inc. Dérivés d'alcynylphényle pour traiter les maladies et les affections ophtalmiques
RU2014151622A (ru) * 2007-10-05 2015-08-20 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
MY167602A (en) 2007-11-01 2018-09-20 Acucela Inc Amine derivatives compounds for treating ophthalmic diseases and disorders
CA2736229C (fr) 2008-09-05 2015-06-09 Acucela Inc. Composants a liaison soufre pour le traitement de maladies et de troubles ophtalmiques
TWI486326B (zh) 2008-10-22 2015-06-01 Acucela Inc 用於治療眼疾和眼病變之連接氮之化合物
ES2897527T3 (es) 2009-07-02 2022-03-01 Acucela Inc Farmacología de moduladores del ciclo visual
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
MX2020001835A (es) 2021-09-09
TW201406707A (zh) 2014-02-16
BR112014027571A2 (pt) 2017-07-18
EP2844636A4 (fr) 2016-03-09
AU2013256029A1 (en) 2014-12-04
JP2015518491A (ja) 2015-07-02
WO2013166449A3 (fr) 2014-01-30
CA2872433C (fr) 2022-06-28
JP2018024702A (ja) 2018-02-15
JP2023059991A (ja) 2023-04-27
US11795136B2 (en) 2023-10-24
US20180346407A1 (en) 2018-12-06
PH12014502449A1 (en) 2015-01-12
CN104411678A (zh) 2015-03-11
HK1246646A1 (zh) 2018-09-14
CA2872433A1 (fr) 2013-11-07
JP2020023535A (ja) 2020-02-13
EP3741742A1 (fr) 2020-11-25
HK1203478A1 (en) 2015-10-30
EP2844636A2 (fr) 2015-03-11
US20140039048A1 (en) 2014-02-06
CN116850163A (zh) 2023-10-10
ZA201408592B (en) 2017-09-27
KR20150013240A (ko) 2015-02-04
US20210171435A1 (en) 2021-06-10
BR112014027571B1 (pt) 2021-08-31
US9957224B2 (en) 2018-05-01
EA201492031A1 (ru) 2015-05-29
US10730825B2 (en) 2020-08-04
MX2014013341A (es) 2015-06-02
EP2844636B1 (fr) 2020-04-22
IL235446A0 (en) 2014-12-31
JP2021075576A (ja) 2021-05-20
ES2792923T3 (es) 2020-11-12
WO2013166449A2 (fr) 2013-11-07
CN107865830A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
HK1203478A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
HK1213192A1 (zh) 用於在人類受試者中治療眼部疾病的方法和裝置
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
HK1209195A1 (en) Contact lens use in the treatment of an ophthalmologic condition
EP2890440A4 (fr) Dispositifs et procédés pour le traitement d'une maladie vasculaire
EP2879617A4 (fr) Dispositifs et méthodes de traitement d'occlusion de l'artère ophtalmique
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
EP2844250A4 (fr) Procédé de traitement et de diagnostic de maladies menant à la cécité
ZA201309557B (en) Methods of treatment for retinal diseases
EP2816984A4 (fr) Dispositif et méthode destinés à traiter le décollement de la rétine et autres maladies de l'oeil
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2906295A4 (fr) Méthodes de traitement de maladies oculaires
EP2867239A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète
EP2849749A4 (fr) Histatine pour cicatrisation de plaies cornéennes et pour affections de la surface oculaire
EP2623494A4 (fr) Agent pour le traitement de maladies oculaires
EP2859898A4 (fr) Agent thérapeutique, méthode de traitement et procédé d'essai pour des maladies associées à l'activation de granulocytes neutrophiles
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
EP3013425A4 (fr) Traitement et diagnostic d'une maladie oculaire
EP2709632A4 (fr) Compositions et procédés pour le traitement de maladies de la peau
HK1219654A1 (zh) 用於治療眼科疾病和病症的方法
IL239078A0 (en) Protein for use in the treatment of eye diseases
EP2934285A4 (fr) Procédés et systèmes de diagnostic de maladie oculaire
EP2943593A4 (fr) Diagnostic et traitement de maladies virales
TH1401006595A (th) วิธีเพื่อการรักษาภาวะเบาหวานขึ้นจอตา และโรคตาอื่น